2026 oncology meetings

SITC, ESMO, ASCO, AACR and ASH 2026. 285 abstracts found by web research and verified against a source page so far, plus each meeting's journal supplement searched live through Crossref where it is indexed. Titles and metadata only.

SITC

SITC Annual Meeting 2026

4–8 Nov 2026, Phoenix

verified abstracts in 1 area

ESMO

ESMO Congress 2026

23–27 Oct 2026, Madrid

146

verified abstracts in 8 areas

ASCO

ASCO Annual Meeting 2026

29 May – 2 Jun 2026, Chicago

verified abstracts in 1 area

AACR

AACR Annual Meeting 2026

17–22 Apr 2026, San Diego

verified abstracts in 1 area

ASH

ASH Annual Meeting 2026

12–15 Dec 2026, New Orleans

verified abstracts in 4 areas

175 of 285 verified abstracts were confirmed on a page we fetched ourselves

Verified abstracts per 2026 meeting, split by how each row was checked. The rest match the text Parallel saved from a page that blocks automated access, mostly ESMO's congress platform.

Found on the cited source pageFound on a second fetched pageMatches only the excerpt saved from a page we could not re-fetch

Rows that failed every check were dropped and are not counted. Source: data/meetings in the project repository, each row linked to its source page.

AACR Annual Meeting 2026

17–22 Apr 2026, San Diego · Cancer Research 86 (7_Supplement)

All 7,489 abstracts, including clinical trial (CT) and late-breaking (LB) abstracts, have Cancer Research supplement DOIs in Crossref.

Non-small cell lung cancer

10 verified · pulled 2026-11-11Open in Non-small cell lung cancer →

CT014
Oral presentation
Perioperative adebrelimab (A) plus chemotherapy (chemo) in resectable stage II-III NSCLC: Phase 3 EFS interim analysis (IA) and molecular residual disease (MRD) analysis
Yi-Long WuNCT04316364adebrelimabchemotherapy
Verified on a second sourceaacrjournals.org
CT015
Oral presentation
Clinical outcomes by genomic markers and ctDNA dynamics with perioperative nivolumab (NIVO) for resectable NSCLC from CheckMate 77T
BohnetCheckMate 77Tnivolumab
Verified on source pageaacrjournals.org
CT020
Oral presentation
Safety and efficacy of Elisrasib (D3S-001), a next generation GDP-bound KRAS G12C inhibitor, as monotherapy in advanced non-small cell lung cancer (NSCLC) previously treated with or without a KRAS G12C inhibitor: Results from a phase 1/2 study
Byoung Chul ChoNCT05410145elisrasib (D3S-001)
Verified on source pageaacrjournals.org
CT021
Oral presentation
Preliminary safety and clinical activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC)
Jonathan Riess (presented by Jonathan W. Riess)NCT06040541zoldonrasib (RMC-9805)
Verified on source pageaacrjournals.org
CT038
Oral presentation
Combination of risvutatug rezetecan and adebrelimab in previously treated advanced nsq-NSCLC without actionable genomic alterations: Results from ARTEMIS-101, a phase 1 study
Hua Zhong (presented by Runbo Zhong)ARTEMIS-101NCT06332170risvutatug rezetecanadebrelimab
Verified on a second sourceaacrjournals.org
CT231
Oral presentation
Dual CD39 and PD-L1 inhibition: Interim results from the phase 2 MATISSE trial of IPH5201 plus durvalumab (durva) and platinum-based chemotherapy (CT) in patients (pts) with resectable NSCLC
Fabrice BarlesiMATISSENCT05742607IPH5201durvalumabplatinum-based chemotherapy
Verified on source pageaacrjournals.org
CT233
Oral presentation
Multi-modal multi-omic analyses reveal mechanisms of immunotherapy resistance in non-small cell lung cancer (NSCLC)
Verified on source pageaacrjournals.org
CT299
Oral presentation
Dirozalkib versus crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): Results from the multicenter, randomized, open-label phase 3 trial
Ying Liu (presented by Haifeng Liu)dirozalkibcrizotinib
Verified on a second sourceaacrjournals.org
CT300
Oral presentation
Taletrectinib in tyrosine kinase inhibitor (TKI)-naïve patients with ROS1+ non-small cell lung cancer (NSCLC): Updated data from TRUST-I and TRUST-II
Lyudmila BazhenovaTRUST-I and TRUST-IItaletrectinib
Verified on source pageaacrjournals.org
CT301
Oral presentation
SHR-A1811 ± adebrelimab as first-line (1L) treatment for advanced HER2-mutant NSCLC: A randomized phase 2 cohort from a phase 1b/2 study
Shun LuNCT05482568SHR-A1811adebrelimab
Verified on source pageaacrjournals.org